Prostate Cancer

CHAARTED2 trial showed an improved progression-free survival in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel, abiraterone acetate, and prednisone.

Investigators aim to identify a clinically useful and safe dose of Illuminare-1 for future studies in surgical cancer care.

Artificial intelligence use in prostate cancer encompasses 4 main areas including diagnostic imaging, prediction of outcomes, histopathology, and treatment planning.

Data from a phase 2 study may support apalutamide plus androgen deprivation in high-risk localized prostate cancer following radical prostatectomy.

Findings support the use of 18F-PSMA-1007 PET/CT in the preoperative workflow of intermediate- and high-risk prostate cancer.

Functional consequences appeared to be lower with HIFU compared with radical prostatectomy in a prospective trial.

Those with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer can now receive enzalutamide in the European Union.

Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.

Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.

Mary-Ellen Taplin, MD, gives her advice on how to achieve work-life balance and make other career advancements in genitourinary cancer.

The positive opinion is supported by findings from the phase 3 EMBARK trial assessing enzalutamide in patients with biochemically recurrent prostate cancer.

Leonard G. Gomella, MD, FACS, discusses new clinical trials that are evaluating novel targeted therapy options for those with prostate cancer.

Findings from a phase 2 trial support the potential survival benefit of BXCL701 plus pembrolizumab in patients with small cell neuroendocrine prostate cancer.

Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.

Findings from the phase 3 PROpel trial suggest that olaparib plus abiraterone acetate may help patients with metastatic castration-resistant prostate cancer live longer, according to Neal Shore, MD, FACS.

Testing for HRR status prior to a diagnosis of metastatic castration-resistant prostate cancer may allow for earlier treatment and potentially greater clinical benefit with olaparib, according to Daniel J. George, MD.

Results from a post hoc sensitivity analysis of the phase 3 ARASENS trial appear to affirm the primary overall survival analysis findings.

Data from the GETUG-AFU 18 trial support high-dose radiation plus long-term androgen deprivation therapy as a standard of care in high-risk prostate cancer.

Four of 5 patients with prostate cancer and ctDNA positivity had disease progression following treatment with darolutamide plus androgen deprivation therapy in a phase 2 trial.

Six months of intensified androgen deprivation therapy plus next-generation anti-androgens may be an attractive option for those with prostate cancer and rising prostate specific antigen levels following prostatectomy.

The overall incidence of bone fractures with prior EBRT to the bone in patients with metastatic castration-resistant prostate cancer remains low.

Additional education on tumor testing and PARP inhibitor therapy is warranted for patients with metastatic castration-resistant prostate cancer, according to Neal Shore, MD, FACS.

Findings support cabozantinib plus atezolizumab as a potential new treatment option for those with metastatic castration-resistant prostate cancer that has progressed on a novel hormonal therapy.

The FDA previously granted approval to frontline olaparib plus abiraterone/prednisone in May 2023 for BRCA1/2–, DDR–altered metastatic castration-resistant prostate cancer.

Darolutamide correlates with a marginally longer length of stay per hospitalization compared with placebo among those with metastatic hormone-sensitive prostate cancer.

While the overall survival between patients receiving cabazitaxel and those receiving Lu-PSMA-617 had negligible difference, the results of the phase 2 TheraP trial supports the use of Lu-PSMA-617 as an alternative treatment for prostate cancer.

Compared with surgery and radiation, focal therapy improves quality of life as well as decreases financial toxicity for patients with prostate cancer.

Including minority populations in clinical trials can be most easily done through outreach and partnerships with other health centers, according to Adam B. Murphy, MD, MBA, MSCI.

Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.

Realigning value-based models to increase reimbursement for hypofractionated radiotherapy in prostate cancer may minimize barriers to access among underserved communities.